Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Is infected with HIV
Is receiving combination anti-retroviral therapy (ART) for ≥6 weeks before study entry with no intended changes to combination ART therapy for 3 months after randomization.
Is vaccine-naïve
You may not be if
Has a history of opportunistic infections ≤12 months before the first vaccination
Has a history of noninfectious acquired immune deficiency syndrome-related illness
Has a history of active hepatitis
Has a history of invasive pneumococcal disease (IPD) or other culture-positive pneumococcal disease ≤3 years before Visit 2 (Day 1)
Has a known hypersensitivity to any component of V116, PCV15, or PPSV23, including diphtheria toxoid
Has a known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Has a coagulation disorder contraindicating intramuscular vaccinations.
Has a recent illness with fever
Has a known cancer malignancy that is progressing or has required active treatment \<3 years before enrollment
Had prior administration of PCV15 or PCV20.
Is expected to receive any pneumococcal vaccine during the study outside of the protocol
Has received systemic corticosteroids for ≥14 consecutive days and has not completed treatment ≥14 days before receipt of study vaccine
Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease
Has received any non-live vaccine ≤14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine ≤30 days after receipt of any study vaccine
Has received any live virus vaccine ≤30 days before receipt of any study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of any study vaccine
Has received a blood transfusion or blood products, including immunoglobulins ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product ≤30 days after receipt of study vaccine
Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
